Susan Johnson
About
Susan Johnson is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Susan Johnson has authored 25 papers receiving a total of 971 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Susan Johnson's work include Diabetes Treatment and Management (15 papers), Diabetes Management and Research (8 papers) and Metabolism, Diabetes, and Cancer (8 papers). Susan Johnson is often cited by papers focused on Diabetes Treatment and Management (15 papers), Diabetes Management and Research (8 papers) and Metabolism, Diabetes, and Cancer (8 papers). Susan Johnson collaborates with scholars based in United States, United Kingdom and Denmark. Susan Johnson's co-authors include Murray Stewart, Mark N. Feinglos, Bo Åhrén, Fred Yang, Julio Rosenstock, Caroline Perry, Deborah T. Cirkel, June Ye, Rhona Scott and Anthony Barnett and has published in prestigious journals such as Diabetes Care, Diabetes and Journal of the American Academy of Dermatology.
In The Last Decade
Susan Johnson
25 papers receiving 944 citations
Peers
Susan Johnson
Elizabeth Round United States
Tadashi Arao Japan
Dahong Yu United States
Soichiro Okubo Japan
Karoline von Websky Germany
Jiandong Zhang China
Anna Di Martino Italy
Julia Möllmann Germany
Keiichi Torimoto Japan
Giuseppe Scavone Italy
Citations per year, relative to Susan Johnson Susan Johnson (= 1×)
peers
Elizabeth Round
Countries citing papers authored by Susan Johnson
Since
Specialization
Citations
This map shows the geographic impact of Susan Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Johnson more than expected).
Fields of papers citing papers by Susan Johnson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Susan Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Johnson. The network helps show where Susan Johnson may publish in the future.
Co-authorship network of co-authors of Susan Johnson
This figure shows the co-authorship network connecting the top 25 collaborators of Susan Johnson. A scholar is included among the top collaborators of Susan Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Johnson. Susan Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Simpson, Eric L., Jonathan I. Silverberg, Audrey Nosbaum, et al.. (2023). 44115 Integrated Safety Analysis of Abrocitinib in 3802 Patients With Moderate-To-Severe Atopic Dermatitis With Over 5000 Patient-Years of Exposure. Journal of the American Academy of Dermatology. 89(3). AB58–AB58.
2.
Reich, Kristian, Jonathan I. Silverberg, Kim Papp, et al.. (2023). Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2056–2066.
3.
Simpson, Eric L., Jonathan I. Silverberg, Audrey Nosbaum, et al.. (2023). 330 Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2 years. British Journal of Dermatology. 188(Supplement_2).
4.
Simpson, Eric L., Jonathan I. Silverberg, Audrey Nosbaum, et al.. (2021). Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. American Journal of Clinical Dermatology. 22(5). 693–707.
5.
Patel, Shrita M., Anne Hickman, Robert Frederich, et al.. (2020). Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy. 11(6). 1347–1367.
6.
Patel, Shrita M., Mary A. Hickman, Robert Frederich, et al.. (2018). Evaluation of Osmotic Diuresis and Volume Depletion Events in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. Diabetes. 67(Supplement_1).
7.
Leiter, Lawrence A., Jorge Luiz Gross, Francis C. C. Chow, et al.. (2017). Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. Journal of Diabetes and its Complications. 31(8). 1283–1285.
8.
Åhrén, Bo, Molly C. Carr, Karen Murphy, et al.. (2017). Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice. 126. 230–239.
9.
Nunez, Derek J., Xiaozhou Yao, Ann C. Walker, et al.. (2016). Glucose and lipid effects of the ileal apical sodium‐dependent bile acid transporter inhibitor GSK2330672 : double‐blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes Obesity and Metabolism. 18(7). 654–662.
10.
Johnson, Susan, Lin Jiang, Xiaozhou Yao, et al.. (2015). Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers. Advances in Therapy. 32(7). 650–661.
11.
Pratley, Richard E., Michael A. Nauck, Anthony Barnett, et al.. (2014). Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. The Lancet Diabetes & Endocrinology. 2(4). 289–297.
12.
Seino, Yutaka, Nobuya Inagaki, Mark Bush, et al.. (2014). A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Current Medical Research and Opinion. 30(6). 1095–1106.
13.
Åhrén, Bo, Susan Johnson, Murray Stewart, et al.. (2014). HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. Diabetes Care. 37(8). 2141–2148.
14.
Rosenstock, Julio, Vivian Fonseca, Jorge Luiz Gross, et al.. (2014). Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care. 37(8). 2317–2325.
15.
Christian, Jennifer, Bhakti Arondekar, Erin Buysman, et al.. (2012). Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. Journal of clinical lipidology. 6(5). 450–461.
16.
Dai, Haiqing, et al.. (2012). The pharmacokinetics and pharmacodynamics of PF-00734200, a DPP-IV inhibitor, in healthy Japanese subjects. International Journal of Clinical Pharmacology and Therapeutics. 50(7). 505–509.
17.
Rosenstock, Julio, Andrew Lewin, Paul Norwood, et al.. (2010). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes. Diabetic Medicine. 28(4). 464–469.
18.
Brown, Devin L., Stuart N. Hoffman, Teresa L. Jacobs, et al.. (2008). CT Angiography is Cost‐Effective for Confirmation of Internal Carotid Artery Occlusions. Journal of Neuroimaging. 18(4). 355–359.
19.
Johnson, Susan, Edward F. Tierney, Chien‐Wen Tseng, et al.. (2006). Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment?. Diabetes Care. 29(8). 1733–1738.
20.
Melby, Christopher L., et al.. (2002). Effect of Carbohydrate Ingestion during Exercise on Post-exercise Substrate Oxidation and Energy Intake. International Journal of Sport Nutrition and Exercise Metabolism. 12(3). 294–309.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Elizabeth Round Breakdown of academic impact, for papers by Tadashi Arao Breakdown of academic impact, for papers by Dahong Yu Breakdown of academic impact, for papers by Soichiro Okubo Breakdown of academic impact, for papers by Karoline von Websky Breakdown of academic impact, for papers by Jiandong Zhang Breakdown of academic impact, for papers by Anna Di Martino Breakdown of academic impact, for papers by Julia Möllmann Breakdown of academic impact, for papers by Keiichi Torimoto Breakdown of academic impact, for papers by Giuseppe Scavone